The two most cross-shopped longevity molecules, and one is a direct precursor to the other. On the Research Quality Score they land just five points apart, both squarely in the Moderate band, with the small edge going to NMN.
NMN is a direct biochemical precursor to NAD+, so comparing them is less "which is better" and more "which point in the same pathway do you target." That closeness shows in the scores: they tie on study design, replication, journal quality, funding independence, and population diversity. NMN's five-point edge comes almost entirely from sample size, reflecting a somewhat larger and more recent set of human trials.
Both sit at Moderate rather than Strong for the same reason: the human research is real and reasonably independent, but the long-horizon outcomes people actually care about, healthspan and aging endpoints, are still immature for both. Short-term biomarker and NAD-level studies exist; decades-long outcome data does not.
Notably, both score 7 out of 10 on funding independence, meaningfully higher than the incretin compounds, because the NAD-precursor literature includes a healthy share of academically funded work rather than being dominated by a single manufacturer.
The real decision is not the two-point-band-mate score gap. It is the pathway question, direct NAD+ versus the NMN precursor route, and the oral bioavailability debate that goes with it. On research quality alone, these two are close to interchangeable in maturity, and the choice belongs to your own reading of the precursor argument, not the RQS.